Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection kit for minute residues of B-cell acute lymphocyte leukemia

A B lymphocyte and minimal residual technology, applied in the field of medical testing, can solve the problems of poor accuracy of acute B lymphocytic leukemia minimal residual, single judgment standard, and high missed detection rate

Inactive Publication Date: 2019-06-14
武汉康圣达医学检验所有限公司
View PDF13 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still a lack of highly sensitive and specific immune markers for efficient and accurate detection of small residual levels, and there is no research on the use of fixed indicators or a single indicator combined with fixed indicators to evaluate patient prognosis and related treatment effects. Research
[0004] At present, the judgment standard of the small residue detection kit used in the prior art is relatively single, and the accuracy for detecting small residues of acute B-lymphoblastic leukemia is poor, and the missed detection rate is high. Therefore, it is urgent to develop a kit with high accuracy. Minimal Residue Detection Reagent for Acute B Lymphocytic Leukemia and Detection Rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection kit for minute residues of B-cell acute lymphocyte leukemia
  • Detection kit for minute residues of B-cell acute lymphocyte leukemia
  • Detection kit for minute residues of B-cell acute lymphocyte leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Preparation of Minimal Residue Detection Kit for Acute B Lymphoblastic Leukemia

[0058] 1. Antibody composition: the composition of the antibody composition is as follows: CD10-PE, CD19-APC, CD20-APC-cy7, CD34-PerCP, CD38-V450, CD45-V500. That is, it consists of monoclonal antibodies against CD10, CD19, CD20, CD34, CD38 and CD45 labeled with PE, APC, APC-cy7, PerCP, V450 and V500 fluorescein in sequence.

[0059] 2. Red blood cell lysate: purchased from BD Company, including the following components: ammonium chloride, potassium dihydrogen phosphate, disodium edetate, and paraformaldehyde.

[0060] 3. Antibody dilution reagent: The composition of the antibody dilution reagent is as follows:

[0061] Fetal bovine serum 1.5% (mass volume percentage content);

[0062] Phosphate buffer 0.01M;

[0063] The pH is 7.2-7.4.

[0064] The preparation method of the antibody dilution reagent is as follows: 0.1g-0.2g of fetal bovine serum is weighed and dissolved in 10m...

Embodiment 2

[0066] Example 2 Detection method for minimal residues of acute B-lymphoblastic leukemia

[0067] This embodiment provides the detection method of the detection kit prepared in the above embodiment 1, specifically as follows:

[0068] (1) Take the numbers of two flow tubes, one is the control tube and the other is the detection tube, and the antibodies CD10-PE, CD19-APC, CD20-APC-cy7, CD34-PerCP, CD38-V450, CD45-V500 Add to the detection tube to ensure that the mass ratio of CD10-PE, CD19-APC, CD20-APC-cy7, CD34-PerCP, CD38-V450, and CD45-V500 is 2:5:5:13:20:40. The total amount of antibodies is 16 μl, including 4 μl of CD10-PE, 2 μl of CD19-APC, 2 μl of CD20-APC-cy7, 4 μl of CD34-PerCP, 2 μl of CD38-V450, and 2 μl of CD45-V500. The antibody can be pre-diluted with antibody dilution reagent; no antibody is added to the control tube.

[0069] (2) Dilute the sample with PBS so that the cell concentration of the sample is 2×10 6 / mL, respectively add 500 μl of diluted sample i...

Embodiment 3

[0077] Example 3 Acute B-lymphocytic Leukemia Minimal Residue Detection Kit and Application of Its Detection Method in Clinical Sample Detection

[0078] The detection kit of Example 1 and the detection method of Example 2 were used to detect 127 clinical samples from different patients with acute B lymphocytic leukemia, such as bone marrow and blood, and each patient's clinical sample detection was provided with a test group and Control group, test group adopt the test kit of embodiment 1 and the detection method of embodiment 2, control group adopt contrast kit and contrast detection method to detect.

[0079] The only difference between the control kit and the kit of Example 1 is that the antibody composition is different. The components of the antibody composition of the control kit are as follows: CD10-PE, CD19-APC, CD34-PerCP, CD38-V450, CD45-V500; The difference between the detection method and the detection method in Example 2 is that the antibody composition added in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical detection, in particular to a detection kit for minute residues of B-cell acute lymphocyte leukemia. The detection kit comprises anti CD10, CD19, CD20, CD34, CD38 and CD45 antibodies labeled by different fluoresceins. The detection kit comprises six monoclonal antibody combinations of leukocyte differentiation antigen, and a fluorescence labeling and flow cytometric detection technology is combined to realize that one-time flow cytometric detection can quickly and accurately identify the level and typing of abnormal cells of the minute residues of the B-cell acute lymphocyte leukemia, the obtained detection index can be used as an intermediate result to intuitively judge the prognosis conditions of B-cell acute lymphocyte leukemia patients, and thus important guiding significance is provided for the formulation of clinical treatment schemes for the leukemia patients.

Description

technical field [0001] The invention relates to the technical field of medical detection, in particular to a small residue detection kit for acute B lymphocytic leukemia. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a malignant clonal proliferative disease of lymphocytes in the early differentiation stage, and it is also a group of highly heterogeneous diseases. Among them, the incidence of acute lymphoblastic leukemia (B-ALL) is about Accounting for 85% of acute lymphoblastic leukemia, it is a serious threat to people's health, so it has been widely taken seriously. At present, the complete remission rate of leukemia has been greatly improved through combined chemotherapy, but leukemia recurrence is the main problem in current leukemia treatment, and the root cause of recurrence mainly comes from the residual leukemia cells in the body. Usually, the state in which a small amount of leukemia cells still remain in the body after the leukemia is remitte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
Inventor 杜雯马耀坤郑金娥商芳影王兰刘钰张秀萍覃磊黄士昂
Owner 武汉康圣达医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com